gene
therapi
experiment
use
genet
manipul
techniqu
correct
error
associ
genet
diseas
modifi
undesir
deoxyribonucl
acid
dna
sequenc
ever
extend
list
genet
diseas
open
door
wide
gene
therapi
new
hope
target
aetiolog
rather
symptom
diseas
plenti
disciplin
gene
therapi
current
discuss
literatur
howev
gener
agreement
main
issu
thoroughli
address
commenc
clinic
trial
novel
gene
therapi
includ
precis
diagnosi
address
genet
error
relat
caus
gene
defect
result
diseas
specif
target
tissu
bodi
dosag
form
design
choic
rout
administr
gene
therapi
approach
corneal
patholog
disord
studi
extens
provid
much
need
progress
specif
corneal
malfunct
unlik
protein
base
therapi
gene
therapi
researchattract
benefit
cheaper
better
control
effici
mani
occas
herp
simplex
viru
type
widespread
human
pathogen
caus
lifelong
recur
diseas
two
hsv
serotyp
exist
distinct
tropism
report
cold
sore
viru
lead
caus
corneal
blind
reject
corneal
graft
develop
world
worldwid
seropreval
rate
rang
popul
acquir
infect
earli
age
adolesc
serotyp
report
infect
cornea
neural
cell
howev
vast
major
hsv
infect
eye
caus
serotyp
soon
infect
viru
develop
lifelong
latenc
sensori
ganglion
trigemin
nerv
trigemin
ganglion
confirm
sever
report
activ
travel
trigemin
ganglion
differ
destin
includ
cornea
howev
grow
bodi
evid
suggest
viru
may
journal
ophthalmolog
abl
remain
quiescent
stage
within
stroma
acyclovir
corticosteroid
normal
prescrib
either
alon
combin
common
hsv
kerat
exampl
prednisolon
drop
prophylact
oral
antivir
drug
common
stromal
kerat
treatment
recurr
epitheli
kerat
includ
cycloplegia
well
antivir
eye
drop
trifluridin
novemb
onlin
record
gene
therapi
clinic
trial
worldwid
provid
journal
gene
medicin
http
wwwabediacom
show
current
activ
clinic
trial
address
differ
ocular
diseas
agerel
macular
degener
choroideraemia
glaucoma
interestingli
recent
progress
made
target
genom
new
antivir
class
medic
articl
review
current
situat
ocular
gene
therapi
infect
includ
viral
nonvir
vector
rout
deliveri
therapeut
gene
target
screen
analyz
public
ocular
gene
therapi
publish
literatur
identifi
promis
pathway
new
techniqu
crucial
research
idea
also
examin
advanc
prospect
ocular
gene
therapi
progress
inadequaci
potenti
solut
field
research
target
genom
promis
novel
strategi
gene
therapi
field
focu
paper
biolog
belong
human
herp
viru
hhv
famili
virion
nm
size
genet
materi
compris
base
pair
encod
gene
arrang
doublestrand
dna
circular
upon
infect
genet
materi
surround
capsid
nm
diamet
tegument
envelop
capsid
viru
uniqu
icosadeltahedr
capsid
compos
capsom
surround
amorph
structur
contain
variou
protein
enzym
tegument
surround
capsid
contribut
virul
viru
virion
surround
lipid
bilay
envelop
acquir
host
embed
glycoprotein
glycoprotein
function
attach
fusion
structur
antiimmun
protein
figur
five
glycoprotein
gb
gc
gd
complex
gh
gl
mediat
entri
host
cell
three
dimension
structur
reveal
use
cryoelectron
tomographi
show
tegument
asymmetr
capsid
close
envelop
one
side
side
distanc
nanomet
tegument
genom
consist
linear
doublestrand
dna
molecul
kb
contain
gene
compos
long
l
short
uniqu
u
sequenc
region
u
l
u
resp
flank
region
intern
termin
repeat
uniqu
sequenc
combin
specif
origin
replic
repeat
includ
termin
repeat
tr
long
tr
l
short
segment
tr
intern
repeat
ir
long
segment
ir
l
short
segment
ir
sequenc
surround
u
l
region
label
ab
b
around
u
region
c
ca
see
figur
b
around
half
genom
sequenc
conserv
howev
mutat
half
gene
report
affect
replic
process
genom
also
contain
pac
signal
sequenc
essenti
pack
dna
viral
capsid
latenc
stage
hsv
lifespan
express
latencyassoci
transcript
lat
switch
gener
gene
express
restrict
exit
dormanc
state
trigger
decreas
immun
due
infect
stress
ultra
violet
uv
radiat
fever
conjunctiva
believ
first
affect
organ
activ
infect
viral
replic
trigemin
ganglia
continu
cluster
differenti
tcell
activ
increas
dna
mend
mechan
caus
latenc
viru
regard
fact
asymptomat
infect
widespread
diagnosi
clinic
symptom
question
laboratori
method
perform
special
virologist
highli
recommend
commonli
use
method
includ
direct
fluoresc
antibodi
test
polymeras
chain
reaction
pcr
cell
cultur
use
vero
cell
line
howev
direct
fluoresc
antibodi
test
report
superior
sensit
pcr
method
better
sensit
cell
cultur
method
howev
pcr
show
higher
degre
specif
use
antibodi
highli
recommend
method
recent
anoth
group
shown
pcr
fluoresc
antibodi
test
equal
sensit
compar
specimen
taken
cornea
scrape
patient
tear
result
pcr
fluoresc
antibodi
test
similar
sensit
neg
predict
figur
treatment
case
typic
combin
medic
inflamm
immun
neovascularis
suppress
agent
togeth
antivir
drug
corticosteroid
use
improv
clinic
sign
due
antiinflammatori
antiangiogenesi
effect
sever
antivir
drug
shown
efficaci
treatment
ocular
kerat
includ
acyclovir
valacyclovir
cidofovir
trifluorothymidin
ganciclovir
first
line
therapi
acyclovir
valacyclovir
epitheli
infect
usual
treat
acyclovir
ointment
two
week
stromal
necrot
nonnecrot
infect
treat
acyclovir
combin
corticosteroid
yet
resist
acyclovir
recent
report
therefor
novel
antivir
drug
highli
demand
ganciclovir
gel
activ
establish
first
case
seri
describ
effect
treatment
prophylaxi
herpet
kerat
commonli
prescrib
antivir
corticosteroid
drug
allevi
symptom
shorten
infect
period
prevent
reactiv
latent
infect
consequ
rais
demand
new
class
innov
power
safe
genet
antivir
drug
howev
longterm
administr
acyclovir
help
decreas
recurr
infect
although
studi
discuss
possibl
produc
vaccin
hsv
serotyp
potenti
treat
ocular
diseas
use
gene
therapi
feasibl
gene
therapi
advantag
prolong
therapeut
effect
tissuetyp
specif
transcript
control
via
specif
regulatori
element
understand
mechan
surviv
overcom
host
immun
gateway
develop
novel
antivir
therapi
primarili
complex
antivir
defenc
mechan
base
innat
adapt
immun
activ
immun
recruit
mechan
immun
cascad
orchestr
mainli
tcell
respons
pathogenesi
antivir
resist
molecul
group
intrins
antivir
immun
recent
emerg
promis
class
virusbattl
research
field
viral
replic
assembl
directli
interrupt
preexist
agent
host
cell
intrins
factor
restrict
factor
directli
imped
normal
viral
lifespan
three
approach
gene
transfer
consid
first
one
system
administr
even
wide
spread
distribut
host
bodi
major
concern
moreov
gene
deliveri
trigemin
ganglion
latenc
requir
high
specif
cross
blood
brain
barrier
nerv
second
local
applic
nake
therapeut
gene
load
vector
third
approach
treat
cornea
ex
vivo
cornea
treat
prior
surgeri
main
advantag
safeti
access
endothelium
even
gene
transfer
perform
vector
must
chosen
modifi
safe
effici
escort
dna
outsid
cell
nucleu
overcom
sever
physic
barrier
obstacl
intern
escap
endocytot
vesicl
movement
cytoplasm
transport
nucleu
vehicl
ocular
gene
therapi
describ
broader
prospect
number
review
therefor
focu
paper
nonetheless
attempt
fill
gap
concentr
latest
advanc
set
futur
direct
vector
type
use
corneal
gene
therapi
corneal
herpet
kerat
clinic
trial
ocular
gene
therapi
util
viral
vector
gene
deliveri
record
exist
clinic
trial
herpet
kerat
gene
therapi
four
class
virus
reportedli
use
ocular
gene
therapi
adenoviru
adenoassoci
viru
retroviru
lentiviru
vector
nevertheless
use
adenoviru
retroviru
limit
due
rel
high
inflammatori
reaction
virus
plu
inabl
transduc
layer
cornea
especi
endothelium
adenoviru
ex
vivo
transduct
human
cornea
adenovir
vector
contain
lacz
report
gene
either
cytomegaloviru
cmv
rou
sarcoma
viru
rsv
transcript
promot
provid
high
transduct
effici
especi
endothelium
variou
approach
develop
modifi
adenoviru
tropism
chang
introduc
adenoviru
vector
lower
immunogen
exampl
modif
capsid
protein
polym
polyethylen
glycol
peg
extend
circul
kinet
murin
model
allow
neutral
adenoviru
vector
antibodi
activ
peg
react
preferenti
termini
lysin
residu
capsid
specif
hexon
fiber
penton
base
protein
result
improv
specif
lower
toxic
moreov
incorpor
laminin
deriv
peptid
polym
modifi
adenoviru
improv
celltyp
target
specif
sever
modif
introduc
adenoviru
improv
perform
gene
therapi
approach
discuss
recent
review
also
adenohiv
human
immunodefici
viru
adenoaav
adenoassoci
viru
hybrid
develop
adenoassoci
viru
current
lead
choic
corneal
gene
therapi
adenoassoci
viru
aav
express
pattern
viru
show
delay
express
transgen
therefor
therapeut
activ
sustain
mani
year
recombin
aav
success
use
deliv
therapeut
molecul
wholethick
rabbit
human
cornea
ex
vivo
gene
therapi
use
aav
vector
decreas
corneal
neovascularis
associ
corneal
infect
review
elsewher
recent
novel
modif
viral
genom
capsid
introduc
optimis
effici
tropism
aav
vector
genom
new
gener
selfcomplementari
aav
vector
contain
coval
bound
hairpin
form
duplex
dna
molecul
power
point
selfcomplementari
aav
vector
longer
depend
host
cell
convert
singlestrand
aav
genom
transcript
activ
doublestrand
form
self
complementari
aav
shown
shorter
lag
time
believ
safer
choic
addit
product
hybrid
pseudotyp
raav
vector
raav
genom
packag
capsid
anoth
aav
serotyp
verifi
mani
report
improv
tissu
specif
reduc
toxic
inflammatori
reaction
outcom
mix
match
process
review
cover
other
new
compar
studi
differ
aav
serotyp
transduct
human
cornea
ex
vivo
use
intrastrom
inject
recent
describ
adenoaav
hybrid
vector
shown
promot
sitespecif
integr
avoid
activ
oncogen
integr
transgen
human
genom
lentiviru
retroviru
lentiviru
retroviru
belong
group
retrovirida
lentiviru
base
vector
popular
choic
gene
deliveri
endothelium
known
profici
transduc
slow
divid
cell
class
viral
vehicl
shown
compet
transduc
primari
human
endotheli
cell
effici
howev
properti
render
unsuit
stromal
herpet
kerat
contrari
success
lentiviru
short
hairpin
rna
ribonucl
acid
deliveri
cornea
use
recent
studi
decreas
induc
angiogenesi
stromal
kerat
observ
addit
lentiviru
use
convey
therapeut
gene
improv
corneal
allograft
endur
ex
vivo
transduct
effici
aav
improv
sever
method
exampl
creat
pocket
depth
use
femtosecond
laser
shown
improv
effici
lentiviru
transduct
stromal
keratocyt
promis
method
antiangiogenesi
agent
improv
vision
qualiti
corneal
transplant
retroviru
lentiviru
genom
singl
strand
rna
encapsul
lipid
envelop
name
retro
come
properti
retrotranscript
linear
doubl
strand
dna
integr
host
genom
retrovir
vector
recommend
transduc
cornea
base
differ
lentivirus
like
hiv
equin
infecti
anaemia
viru
eiav
felin
immunodefici
viru
fiv
abil
retroviru
transduc
human
cornea
confirm
sever
report
yet
abl
infect
slow
nondivid
cell
henc
use
endothelium
transduct
hand
microrna
success
transduc
corneal
epitheli
cell
recent
report
retrovir
vector
well
known
integr
genom
host
achiev
stabl
transgen
express
properti
use
treat
chronic
infect
long
last
gene
express
benefit
gene
deliv
endothelium
inject
anterior
chamber
eye
retrovir
vector
genet
modifi
isol
ci
sequenc
requir
transfer
viral
genom
tran
sequenc
encod
viral
protein
produc
replic
incompet
vector
howev
recombin
event
gener
replic
viru
main
safeti
concern
due
pathogen
natur
hiv
nake
dna
neovascularis
result
immunostimul
caus
sever
vision
opac
earli
studi
show
transfer
nake
complementari
dna
cdna
encod
vascular
endotheli
growth
factor
vegf
receptor
antagonist
eye
shown
journal
ophthalmolog
block
format
blood
vessel
dna
shown
access
epithelium
stroma
transcrib
angiogenesiscontrol
drug
topic
applic
dna
plasmid
encod
interferon
alpha
effect
ocular
neovascularis
time
dose
depend
manner
abl
antagon
reactiv
microinject
intraocular
inject
dna
plasmid
encod
interleukin
reduc
angiogenesi
immunoinflammatori
lesion
result
infect
mice
deliveri
cornea
microinject
differ
corneal
tissu
describ
sever
research
report
polylact
coglycol
acid
plga
nanoparticl
shown
effici
nontox
sustain
form
gene
therapi
progress
reduc
murin
rat
corneal
neovascularis
nanocarri
nanoparticl
use
mani
drug
deliveri
system
hyaluron
acid
chitosan
nanoparticl
load
genet
medicin
rnai
dna
plasmid
use
corneal
gene
therapi
albumin
nanoparticl
abl
reduc
neovascularis
week
signific
toxic
control
releas
silica
nanoparticl
impregn
antivir
drug
acyclovir
shown
promis
approach
howev
test
biosynthet
corneal
transplant
suggest
design
similar
dosag
form
gene
therapi
deliveri
cornea
copolym
poli
lactic
glycol
acid
pgla
nanoparticl
prove
good
vehicl
gene
therapi
low
molecular
weight
chondroitin
sulphatehyaluronan
nanoparticl
shown
compet
deliv
green
fluoresc
protein
gfp
encod
plasmid
rabbit
cornea
electropor
electropor
method
employ
high
field
strength
squarewav
electr
puls
allow
penetr
therapeut
molecul
genet
materi
therapeut
molecul
appli
surfac
cornea
electr
puls
assist
diffus
process
method
involv
biochem
agent
therefor
consid
safer
choic
electropor
caus
sever
cell
damag
induc
immunogen
reaction
altern
ultrasound
enhanc
gene
transfer
mammalian
corneal
cell
vitro
vivo
without
cell
damag
facilit
viral
nonvir
gene
convent
drug
deliveri
cornea
electropor
success
use
deliv
gene
mice
cornea
vivo
gene
transfer
endothelium
stromal
keratocyt
report
rat
nevertheless
high
voltag
hazard
femtosecond
laser
applic
femtosecond
laser
becom
accept
corneal
refract
surgeri
transplant
due
high
precis
safeti
compar
convent
laser
femtosecond
laser
use
creat
pocket
corneal
surfac
assist
deliveri
therapeut
agent
use
deliv
vector
stroma
therefor
suggest
use
chronic
stromal
herpet
kerat
condit
latenc
stroma
recent
argu
femtosecond
infrar
titanium
sapphir
laser
beam
shown
enhanc
vivo
gene
deliveri
method
shown
effect
assist
closur
corneal
neovascularis
rabbit
synthet
peptid
vector
system
antibodi
target
use
addit
liposom
gene
transfer
techniqu
use
antibodi
certain
cellspecif
use
target
specif
corneal
layer
liposom
contain
plasmid
dna
coat
antibodi
form
immunospecif
vector
target
specif
receptor
given
cell
type
exampl
target
endothelium
improv
allograft
surviv
liposom
transferrin
target
endocyt
transferrin
receptor
use
success
modul
murin
corneal
allograft
reject
therapeut
transgen
vector
system
base
synthet
peptid
polylysin
molossin
shown
deliv
dna
plasmid
rabbit
cornea
endotheli
cell
direct
applic
ex
vivo
gene
gun
gene
gun
method
also
known
particl
bombard
microprojectil
gene
transferor
gene
gun
ballist
transfer
gene
gun
use
transfer
cdna
coat
gold
particl
epithelium
howev
use
gene
gun
transduc
endothelium
shown
sever
damag
dendrim
liposomebas
deliveri
dendrim
macromolecul
characteris
extens
branch
three
dimension
structur
accommod
genet
materi
henc
use
drug
deliveri
activ
polyamidoamin
dendrim
carri
dna
plasmid
transduc
corneal
endothelium
direct
applic
cornea
liposom
gene
transfer
endothelium
report
rel
ineffici
vector
limit
use
corneal
gene
therapi
howev
polyethylen
glycolmodifi
liposom
aid
ultrasound
improv
effici
drug
deliveri
bodi
work
gene
therapi
corneal
disord
establish
potenti
find
new
gene
therapi
drug
deliveri
cornea
gene
therapi
prefer
appli
local
avoid
system
complic
perform
ex
vivo
eye
bank
improv
graft
surviv
prior
transplant
patient
herpet
kerat
histori
topic
applic
may
avoid
modul
system
immun
respons
like
induc
untoward
corneal
inflamm
system
side
effect
sever
strategi
use
target
certain
viral
envelop
compon
replic
process
protein
result
inflamm
gene
therapi
work
herpet
kerat
target
chronic
inflamm
journal
ophthalmolog
process
howev
less
signific
amount
data
exist
target
viru
genom
neovascularis
gene
therapi
approach
combat
direct
inflamm
process
herpet
kerat
infect
latent
viru
reactiv
result
chronic
ocular
immun
respons
specif
lymphocyt
produc
mainli
produc
thelper
cytokin
herpet
stromal
kerat
chronic
inflamm
caus
edema
neovascularis
scar
moreov
cornea
transplant
oper
perform
replac
damag
cornea
immunogen
herpet
kerat
infect
reduc
howev
reduc
host
sensit
prefer
reason
number
studi
explor
abil
gene
therapi
deliv
specif
antiinflammatori
mediat
brief
tabl
success
attempt
target
ocular
gene
therapi
arrang
chronolog
order
highlight
progress
achiev
reduc
inflamm
andor
neovascularis
result
desir
regress
herpet
kerat
sign
addit
surviv
rate
corneal
allograft
also
improv
nevertheless
must
consid
diseas
mask
actual
cure
therefor
interest
recent
year
direct
viral
genom
detail
section
target
genom
dna
damag
respons
mechan
cell
correct
damag
elimin
sever
damag
cell
activ
program
cell
death
mechan
dna
damag
mechan
involv
process
excis
damag
area
cell
cycl
arrest
prevent
pass
mutat
sequenc
transcript
level
control
howev
sever
injuri
caus
cell
undergo
apoptosi
dna
repair
mechan
includ
direct
repair
base
excis
repair
nucleotid
excis
repair
doublestrand
break
repair
crosslink
repair
detail
descript
mechan
discuss
elsewher
detail
understand
mechan
allow
discoveri
new
genet
agent
possibl
antivir
candid
target
genom
degrad
use
sever
techniqu
report
includ
use
ribozym
antisens
oligodeoxi
nucleotid
morpholino
antisens
nucleotid
small
interf
rna
sirna
aptam
home
endonucleas
figur
ribozym
rna
molecul
intrins
enzymat
activ
promot
varieti
reaction
without
aid
protein
cofactor
usual
involv
cleav
splice
rna
molecul
therefor
use
gene
therapi
shown
activ
improv
surviv
rate
mice
ribozym
less
potent
sirna
howev
evolut
new
ribozym
rel
better
specif
bind
two
advantag
antisens
oligodeoxynucleotid
antisens
oligodeoxynucleotid
short
synthet
dna
consist
nucleotid
inhibit
protein
biosynthesi
specif
target
complementari
stretch
rna
principl
abl
interfer
step
nucleic
acid
metabol
preferenti
block
translat
antisens
oligonucleotid
use
moreov
topic
treatment
found
reduc
cultur
lymphocyt
vivo
mice
system
administr
success
howev
topic
blockad
may
interfer
antivir
respons
ultim
lead
recurr
herpet
kerat
morpholino
antisens
oligonucleotid
antisens
oligonucleotid
morpholino
function
translat
arrest
phosphorodiamid
morpholino
oligom
pmo
subclass
antisens
oligonucleotid
modifi
includ
phosphorodiamid
linkag
morpholin
ring
demonstr
limit
offtarget
effect
favour
base
stack
high
duplex
stabil
high
solubl
cell
permeabl
hybrid
complex
recent
promis
studi
target
translat
site
genom
mice
peptid
conjug
pmo
show
better
inhibit
acyclovir
small
interf
rna
sirna
abil
transfect
synthet
sirna
suppress
express
specif
transcript
use
techniqu
probe
gene
function
mammalian
cell
plasmid
encod
small
hairpin
rna
extens
use
gene
therapi
consequ
sirna
use
target
virus
sever
studi
target
neovascularis
result
herpet
kerat
kim
et
al
shown
sirna
vegfa
inject
complet
prevent
stromal
epitheli
kerat
day
infect
plasmid
dna
topic
conjunctiv
complet
prevent
stromal
epitheli
kerat
plasmid
dna
mice
topic
suppress
lesion
use
transgen
suppress
lesion
antisens
oligonucleotid
mice
subepitheli
inject
reduct
herp
simplex
kerat
sign
day
infect
mice
intraperiton
inject
transgen
complet
surviv
prevent
corneal
scar
day
infect
andor
reduc
lesion
angiogenesi
addit
sirna
target
glycoprotein
e
express
mediat
celltocel
spread
immun
evas
shown
suppress
activ
infect
vitro
knockdown
glycoprotein
also
achiev
use
sirna
infect
human
conjunctiv
epithelium
vitro
use
vitro
plaqu
test
replic
also
inhibit
sirna
gene
encod
larg
subunit
ribonucleotid
reductas
although
sirna
base
approach
highli
specif
yet
still
expens
realli
reproduc
due
variabl
effici
transient
express
natur
technolog
aptam
oligonucleotid
sequenc
capac
recogn
specif
target
molecul
high
affin
specif
refer
aptam
begin
emerg
class
molecul
compet
antibodi
therapeut
diagnost
applic
recent
studi
shown
vivo
inhibit
rat
corneal
angiogenesi
target
nucleaseresist
rna
aptam
home
endonucleas
target
endonucleas
genom
excis
emerg
new
concept
antivir
gene
therapi
home
endonucleas
group
restrict
enzym
encod
intron
intein
recognit
site
rare
howev
custom
made
endonucleas
name
meganucleas
made
target
specif
viral
sequenc
gene
therapi
antihsv
custommad
meganucleas
recent
shown
prevent
infect
cultur
cell
wildtyp
target
sever
viral
compon
propos
promis
target
antivir
drug
discoveri
target
highli
select
effect
manner
deliveri
gene
encod
agent
capabl
disrupt
numer
biolog
process
key
concept
target
revers
transcriptas
block
transcript
process
viral
surfac
receptor
also
repres
attract
target
exampl
cc
chemokin
receptor
type
major
coreceptor
import
effici
viral
entri
cell
addit
number
replic
protein
serv
interest
target
gene
therapi
thymidin
kinas
ribonucleotid
reductas
deoxyuridin
diphosphatas
uracildna
glycosylas
alkalin
nucleas
strategi
includ
inhibit
dna
polymeras
specif
peptid
small
molecul
nuclear
localis
signal
molecul
inhibit
proteinprotein
interact
singl
substitut
one
subunit
proteinprotein
interfac
complet
disrupt
subunit
interact
exampl
interrupt
hydrogen
bond
subunit
pol
may
repres
interest
target
new
drug
potenti
treatment
mani
genet
diseas
viral
infect
progress
elev
attent
awar
toward
new
era
highli
special
treatment
fact
gene
therapi
clinic
evalu
promot
massiv
research
conduct
current
anim
model
well
establish
therapeut
gene
molecul
transfer
cornea
direct
applic
nake
dna
electr
puls
ballist
transfer
gene
gun
viral
nonvir
vector
sever
creativ
combin
approach
choic
appropri
vector
target
essenti
success
gene
therapi
express
profil
bioavail
biodegrad
specif
vector
main
variabl
current
evalu
sever
research
group
achiev
ideal
combin
success
gene
therapi
requir
choic
right
vector
particular
diseas
choic
made
base
abil
target
cell
uptak
vector
express
transgen
cellspecif
manner
mainten
express
period
time
need
tackl
diseas
chronic
case
requir
surgeri
local
applic
cornea
usual
prefer
howev
pretreat
cornea
ex
vivo
eye
bank
specialis
area
train
staff
new
practic
approach
corneal
gene
therapi
help
decreas
transplant
reject
due
chronic
herpet
kerat
minimis
risk
vivo
gene
therapi
